Data as of Q4 2025 (Dec 31, 2025)

Ally Bridge Group (NY) LLC

โ€ขCIK: 1822947โ€ขFiling: Q4 2025

**Ally Bridge Group (NY) LLC** manages $87M across a concentrated portfolio of 16 positions. The fund exhibits significant exposure to real estate and specialized credit, with top holdings including REPL at $11.7M and ABVX at $9.4M. Further notable allocations include SLNO ($7.8M) and CMPS ($7.6M), indicating a targeted, high-conviction approach to niche market opportunities. This structure suggests a focus on generating alpha through deeply researched, sector-specific investments.

Total AUM
$60.5M
+ $26.8M in options
QoQ Performance
-38.9%
Positions
12
+ 4 options
Top 10 Concentration
83.2%
Latest Filing
Q4 2025

Top Holdings Allocation

REPL
ABVX
SLNO
CMPS
ATAI
IVA
NERV
PRAX
REPL13.4%
ABVX10.8%
SLNO8.9%
CMPS8.7%
ATAI8.0%
IVA8.0%
NERV7.6%
PRAX6.7%

๐Ÿ“ˆ Biggest Buys

ABVX
ABIVAX SA
NEW
10.8% of portfolio
IVA
INVENTIVA SA
NEW
8.0% of portfolio
NERV
MINERVA NEUROSCIENCES INC
NEW
7.6% of portfolio
EWTX
EDGEWISE THERAPEUTICS INC
NEW
5.5% of portfolio
QURECALL
UNIQURE NV
NEW
5.5% of portfolio

๐Ÿ“‰ Biggest Sells

PRAX
PRAXIS PRECISION MEDICINES I
-80.1%
6.7% of portfolio
REPLCALL
REPLIMUNE GROUP INC
-66.7%
13.4% of portfolio
TSHACALL
TAYSHA GENE THERAPIES INC
-73.7%
3.2% of portfolio
EPRX
EUPRAXIA PHARMACEUTICALS INC
-56.5%
3.4% of portfolio
SLNO
SOLENO THERAPEUTICS INC
-32.8%
8.9% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

MDGL
MADRIGAL PHARMACEUTICALS INC
SOLD
$15.0M
ASND
ASCENDIS PHARMA A/S - ADR
SOLD
$10.2M
LENZ
LENZ THERAPEUTICS INC
SOLD
$8.2M
AMLX
AMYLYX PHARMACEUTICALS INC
SOLD
$5.9M
MNPR
MONOPAR THERAPEUTICS INC
SOLD
$5.3M
+8 more exited positions

Changes from Q3 2025

NEW7 new positions
โ†‘1 increased
โ†“7 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023